Genomics Market


DeciBio’s Spatial Omics Q&A with Brian McKelligon of Akoya Biosciences

  Akoya Biosciences has gone public, will be joining the Russell 3000, penned agreements with Nikon, Zeiss, CrestOptics, Andor, and AstraZeneca, and discovered novel immunotherapy markers in collaboration with astronomists

The Galaxy’s Guardians with Dr. Chris Mason

I recently had a chance to sit down for a really fun conversation with my friend Dr. Chris Mason. Chris is a professor at Weill Cornell Medicine, and he works

DeciBio’s Spatial Omics Q&A with Terry Lo and George Emanuel of Vizgen

  This past Thursday, May 6, Vizgen launched their MERFISH (Multiplexed Error-Robust Fluorescence in situ Hybridization) Data Release Program and released the first available dataset, the Mouse Brain Receptor Map.

AGBT 2021 Catch-Up with Jeffrey Rosenfeld

  Jeffrey Rosenfeld, Ph.D. has extensive experience in genomics and bioinformatics. Over his 15-year career in genomics, he has worked on a wide range of biological and genetic projects including

10X Genomics Dominates the Single-Cell Landscape While Competitors Look for a Niche

  Today, we published the 4th edition of our single-cell genomics report. We estimate that the global single-cell genomics manufacturer market reached $630M in 2019 and will grow at 23%

A 2020 Look at 3 Trends in Immuno-Oncology Biomarkers

We recently added >300 new trials to our I/O biomarker clinical trial tracker, The I/O BioMAP, bringing our running total to ~2,700 studies, and providing new data that sheds light

NGPS brings Proteins Back on the Map

Los Angeles, CA March 2, 2020 – This morning, Quantum Si introduced a potentially highly disruptive instrument, an equivalent to NGS for high-throughput protein sequencing. The company is part of

AGBT 2020: DeciBio Highlights – Spatial Profiling Reloaded & MGI Unleashed

Marco Island, FL February 27, 2020 – AGBT’s 20th Anniversary didn’t disappoint, with many provocative sessions and product launches. In many ways, #AGBT20 mirrored the #AGBT19 vintage! This year, however,

How KKR Made a ~3x Return in 4 Years by Investing in Research Tools

  KKR made headlines late last year with the exit of their investment in LGC Group, a UK-based biochemical standards and reagents provider. Sources say KKR acquired LGC in December